A powerful approach to uncover immune checkpoint receptors using the Retrogenix technology

Background

Many key immune checkpoint interactions are not yet fully characterised – hampering efforts to discover and develop new, targeted immuno-therapies – due to the low success rates of standard techniques in identifying specific ligand-receptor pairing. Retrogenix’s cell microarray technology (as known as plasma membrane protein array screening) has been successful in identifying key receptors for both orphan ligands and for phenotypic molecules discovered using functional studies.

Here we demonstrate the power of the Retrogenix approach in uncovering immune checkpoint interactions using the ligands CTLA4 and CD27.

 

Methods

Both CTLA4-hFc and CD27-hFc were screened for binding with approx 4,500 human plasma membrane proteins that were individually over-expressed in HEK293 cells as outlined below.

Primary screens: 13 slides were spotted in duplicate with expression vectors encoding full-length, unfused plasma membrane proteins. Human HEK293 cells were overlaid and reverse-transfected. Slides were then fixed. Each Fc-tagged test ligand was added to the slides and gain of binding detected using an Alexafluor647 anti-hIgGFc secondary antibody.

Confirmation screen: Positive ‘hits’ were confirmed by sequencing, re-expressed on fresh slides and tested for specificity along with appropriate experimental controls.

Results

CTLA4: Both isoforms of the CD86 receptor were successfully identified along with the CD80 receptor. No secondary targets or false positive results were reported using Retrogenix.

CD27: The Retrogenix screen correctly identified the known receptor, CD70, along with two further specific, weak intensity hits. These data point to an additional two receptors for CD27 which warrant further investigation.

The results of this study were presented as a poster at PEGS Boston 2016 which is available to download here.

Impact

By using previously characterised interactions, these results demonstrate an efficient method for rapidly identifying specific ligand-receptor binding in human cells. The technology is routinely used to uncover novel targets in the development of immuno-oncology therapies.

To discuss a project with a member of our science team please get in touch. Alternatively, return to our immune checkpoint pairing applications page.

Pfizer
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
BioInvent
AstraZeneca
Bluebird Bio
glycotope_logo
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
MedImmune
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
Thank you again for your professionalism, for a fine analysis, and for our enjoyable scientific exchanges.
Professor Gunnar Lindahl, Lund University, Sweden